SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K for date October 11, 2002
Novartis AG
(Name of Registrant)
Lichtstrasse
35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F o
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No ý
Investor Relations | Novartis International AG CH-4002 Basel Switzerland Karen J Huebscher, PH.D. Tel +41 61 324 8433 Nafida Bendali Tel +41 61 324 3514 Sabine Moravi, MBA Tel + 41 61 324 8989 Silke Zenter Tel +41 61 324 8612 Francisco Bouzas Tel +41 61 324 8444 Fax + 41 61 324 8844 Internet Address: http://www.novartis.com |
INVITATION FOR MEETING, WEBCAST & TELEPHONE CONFERENCE
R&D Day and Q3 2002 Results Review
Dear Investor
We are pleased to invite you to attend the Novartis R&D Day and review of Q3 2002. You may participate in person, via webcast or by teleconference. Please see the preliminary program on page 2.
Date: | October 17, 2002 | |
Time: |
09.00 a.m. New York 02.00 p.m. UK 03.00 p.m. Switzerland |
|
If attending in person: registration and coffee begin at 8:30 a.m Webcast or dial-in: test connection 10 minutes before program start |
||
Location |
The Waldorf Astoria Hotel 301 Park Avenue Grand Ballroom (3rd Floor; Lexington Ave entrance) New York, NY 10022 |
|
Phone numbers: |
Switzerland: +41 91 610 4111 |
|
United Kingdom: +44 (0) 207-866-4111 |
||
Europe Free-phone +800 2467 8700 |
||
US: +1 800 860 2442 |
||
Canada: 866-519-5086 |
You may also access the conference call as a live webcast on the Internet at: http://www.novartis.com/investors (under Upcoming Event). This information will be available for tests and for the submission of questions in advance from October 15, 2002.
Preliminary Agenda
All times Eastern Standard/New York
9:00 AM Introduction and Q3 Results
9:15 AM Review of recent product launches
10:35 AM Q&A (in person or via webcast only)
11:00 AM Break
11:30 AM Development/Functional Genomics/Conclusion
1:30 PM Presentations conclude
Poster / booth session & luncheon
2:30 PM Therapeutic area breakout sessions (Oncology, Transplant)
[Programs will be taped and posted to the internet site October 18, 2002.]
3:30 PM End of R&D Day
Program presenters will include Daniel Vasella and others from senior management of Novartis.
* * * * * * * * * * * * * * *
Internet playback of presentations and therapeutic area breakout sessions may be viewed from the following times at www.novartis.com
Date: | Friday, October 18, 2002 | |
Time: |
2:00 p.m. Switzerland 1:00 p.m. UK 8:00 a.m. New York |
If you have not responded yet to attend the presentations in person
and would like to do so, the reply form is attached for your use.
Novartis
Pharmaceutical Research & Development Day
Thursday,
October 17
The Waldorf Astoria HotelGrand Ballroom
New York, NY
o I will attend the New York Presentation
o I will follow the presentations on the Internet (a test link will be sent to you prior to the R&D Day)
First Name | ||
Name |
||
Company |
||
Job Title |
||
Country |
||
Phone |
||
Fax |
||
To confirm your attendance, please e-mail or fax this form to Novartis Investor Relations by October 10, 2002.
E-mail: gabriella.gruber@group.novartis.com
Fax: +41 61 324 84 44, Attention: Gabriella Gruber
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Novartis AG | ||||
Date: October 11, 2002 | By: | /s/ MALCOLM B. CHEETHAM |
||
Name: | Malcolm B. Cheetham | |||
Title: | Head Group Financial Reporting and Accounting |